In response to an ongoing review, the European Medicines Agency (EMA) has issued a statement regarding GLP-1 receptor agonists. These medications are commonly used in the treatment of type 2 diabetes. The review is being conducted to assess the potential risk of pancreatic adverse events associated with the use of GLP-1 receptor agonists.
The EMA highlights the importance of balancing the benefits and risks of these medications and emphasizes that patients should continue to follow their prescribed treatment until further information is available.
The EMA reassures healthcare professionals and patients that they are actively monitoring the situation and will provide updates as necessary, ensuring the safety and well-being of individuals receiving GLP-1 receptor agonist therapy.